BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered pathology, today announced the strategic expansion of...
WHO recognition of “etaroleucel” (CELZ-101) builds on prior “olastrocel” (CELZ-201) milestone, reinforcing platform credibility and supporting multi-program executionPHOENIX, Feb. 10,...
Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary...
Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™...
Advisory Board Members Will Provide Strategic Clinical Insights to Further Advance the TAMP™ Therapy Platform in Clinical Indications of High...
AGOURA HILLS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- via IBN — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the...
Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA...
Hans T. Schambye Chief Executive Officer, BOOST Pharma Advancing development of lead candidate BT-101, a potential disease-modifying treatment for Brittle...
Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency...
SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed ESTERO, FLORIDA / ACCESS...
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a...
-Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal...
New appointment strengthens executive leadership commensurate with launch of CARDAMYST™ (etripamil) nasal sprayMONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) --...
Flavio Mantelli, MD, PhD, OKYO Pharma Chief Medical Officer Dr. Mantelli will lead the clinical and regulatory strategy to advance...
Second implantation at Harborview Medical Center in Seattle marks continued progress in the FDA-approved study informed by promising results from...
Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99...
Protocol Expansion Broadens Phase 3 HERO Trial Eligibility Criteria to Include Children Ages 7+ in the United StatesSAN DIEGO, Feb....
Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN Nes-Ziona, Israel, Feb....
The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and...